McTaggart Steven J, Atkinson Kerry
Queensland Child & Adolescent Renal Service, Royal Children's Hospital, Australia.
Nephrology (Carlton). 2007 Feb;12(1):44-52. doi: 10.1111/j.1440-1797.2006.00753.x.
Mesenchymal stem cells (MSC) are non-haematopoietic cells that are prevalent in the adult bone marrow but can also be isolated from a variety of other postnatal tissues. MSC are non-immunogenic and are immunosuppressive, with the ability to inhibit maturation of dendritic cells and suppress the function of naïve and memory T cells, B cells and NK cells. In addition to their immunomodulatory properties, MSC are capable of differentiating into various tissues of mesenchymal and non-mesenchymal origin and migrating to sites of tissue injury and inflammation to participate in tissue repair. A number of studies in animal models of cardiac injury, stroke and ischaemic renal injury have demonstrated the clinical potential of MSC in tissue regeneration and repair. MSC are currently being evaluated in various preclinical and clinical studies in humans and offer significant potential as a novel cellular therapy for tissue regeneration and immunological conditions. The present review focuses on the unique immunomodulatory and regenerative properties of MSC and their potential role in the treatment of kidney disease.
间充质干细胞(MSC)是一种非造血细胞,在成人骨髓中普遍存在,但也可从多种其他出生后组织中分离得到。MSC不具有免疫原性且具有免疫抑制作用,能够抑制树突状细胞成熟,并抑制初始和记忆T细胞、B细胞及自然杀伤细胞(NK细胞)的功能。除了免疫调节特性外,MSC还能够分化为间充质和非间充质来源的各种组织,并迁移至组织损伤和炎症部位参与组织修复。多项针对心脏损伤、中风和缺血性肾损伤动物模型的研究已证明MSC在组织再生和修复方面的临床潜力。目前,MSC正在人体的各种临床前和临床研究中接受评估,作为一种用于组织再生和免疫相关病症的新型细胞疗法具有巨大潜力。本综述重点关注MSC独特的免疫调节和再生特性及其在肾脏疾病治疗中的潜在作用。